Fig. 6

SCD1 inhibition efficiently targets melanoma stem cells and reverted their resistance to MAPK inhibitors. a) Efficiency of silencing of SCD1 analyzed by qRT-PCR performed on M14 cells grown in 2D for 96 h; b) Gene expression of nanog, cd133, jarid1b and oct4 after SCD1 silencing in M14 spheroids determined by qRT-PCR; c) Representative western blotting analysis of total lysates obtained from M14 silenced and treated with BRAFi/MEKi showing SCD1 and YAP/YAZ protein expression; d) Gene expression analyses of YAP/TAZ gene targets performed on M14 spheroids SCD1 silenced and treated with BRAFi/MEKi combination. The results confirmed that SCD1 inhibition by silencing partially reverts the enrichment of YAP/TAZ gene targets induced by MAPKi exposure; e) Western blotting of nuclear and cytosolic fractions obtained from M14 spheroids treated with BRAFi/MEKi in presence of SCD1 silencing (left panel) or simultaneously treated with MF-438 (right panel). Densitometric analyses of western blotting showed as a fold-change vs relative CTRL